Development of an immune-related prognostic biomarker for triple-negative breast cancer. (31st December 2022)

• Record Type: Journal Article
• Authors: Zhang, Yan; Wang, Quan; Yang, Wei-Kang; Wang, Yong-Si; Zhou, Qiao; Lin, Jie; Wei, Xu-Xuan; Liang, Tian; Liu, Tongtong; Fan, Wen-Tao; Liang, Li; Xu, You-Nian
• Is Part Of: Annals of medicine. Volume 54:Number 1(2022)
• Page Start: 1212
• Page End: 1220
• Publication Date: 2022-12-31
• Subjects: Breast cancer -- microenvironment (ME) -- prognosis (carcinoma) -- biomarker (BM) -- immunotherapy; Medicine -- Periodicals; 610
• DOI: 10.1080/07853890.2022.2067894
• Languages: English
• ISSNs: 0785-3890

Abstract

Abstract: Purpose: Oncology studies employing digital dissection methodologies have provided some insight on the biological features of tumor microenvironment of Triple-negative breast cancer (TNBC), but molecular diagnostics rarely have therapeutic impact. We aimed to identify a novel prognostic biomarker to investigate immune characteristics of TNBC using transcriptomic features. Patients and Methods: We extracted whole transcriptome from breast cancer tissue of 30 TNBC patients and then used bioinformatics approaches to characterize the different immune cell contents in tumor tissue and para-cancerous tissue. We extract 2 indicators to describe the major differences in immune infiltration in the microenvironment between tumor tissue and para-cancerous tissue. We then combined the 2 indicators that represent the levels of increased and decreased infiltration in each sample to obtain the Immune Infiltration Score (IIS). Then we compared the tumor-infiltrating immune cell contents and immune infiltrating status in TNBC samples with CIBERSORT and ESTIMATE score to validate the IIS. Finally, 132 TNBC patients from the Cancer Genome Atlas program (TCGA) dataset was used to validate the predictive power of IIS. Results: 4 types of upregulated and 4 types of downregulated immune cells were identified in the tumor tissue samples of the TNBC patients. Then we developed a novel biomarker, IIS. Results showed that IIS score can clearly separate cancer and para-cancerous tissue. Using the same cutoff value of 0 in the TNBC-TCGA cohort, we show that those patients with a higher IIS had significantly higher PD-L1 expression and shorter progression-free survival time than those with a lower IIS value, indicating IIS score can be generalized to other TNBC datasets. Conclusion: we explored the immune infiltration landscape in 30 TNBC patients and provided IIS as a novel and reliable biomarker to evaluate the progression-free survival and prognosis of the TNBC patients.